Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue (2019 - 2021)

Historic Non-Current Deffered Revenue for Harmony Biosciences Holdings (HRMY) over the last 3 years, with Q1 2021 value amounting to $192000.0.

  • Harmony Biosciences Holdings' Non-Current Deffered Revenue changed N/A to $192000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $192000.0, marking a year-over-year change of. This contributed to the annual value of $212000.0 for FY2020, which is 2613.24% down from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Non-Current Deffered Revenue stood at $192000.0 for Q1 2021.
  • Harmony Biosciences Holdings' Non-Current Deffered Revenue's 5-year high stood at $305000.0 during Q3 2020, with a 5-year trough of $192000.0 in Q1 2021.
  • Its 3-year average for Non-Current Deffered Revenue is $249000.0, with a median of $249500.0 in 2019.
  • Over the last 5 years, Harmony Biosciences Holdings' Non-Current Deffered Revenue had its largest YoY gain of 2613.24% in 2020, and its largest YoY loss of 2613.24% in 2020.
  • Quarter analysis of 3 years shows Harmony Biosciences Holdings' Non-Current Deffered Revenue stood at $287000.0 in 2019, then fell by 26.13% to $212000.0 in 2020, then fell by 9.43% to $192000.0 in 2021.
  • Its Non-Current Deffered Revenue was $192000.0 in Q1 2021, compared to $212000.0 in Q4 2020 and $305000.0 in Q3 2020.